Charter Life Sciences
VC Fund
Santa Clara, United States
Charter Life Sciences is a clinical-stage venture capital firm focused on investments in early-stage opportunities.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Charter Life Sciences invests in
Stages Charter Life Sciences invests in
Countries Charter Life Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Barr Dolan
|
|||
Andrew K. Klatt
|
|||
Donald C. Harrison
|
|||
Gino Di Sciullo
|
|||
Jean L. Kanerva
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 8 (47%)
- Medical 7 (41%)
- Biotechnology 5 (29%)
- Medical Device 4 (24%)
- Therapeutics 3 (18%)
Stage
- Series B 9 (53%)
- Series A 3 (18%)
- Series C 2 (12%)
- Series D 1 (6%)
- Funding Round 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Barr Dolan
Managing Partner
|
Managing Partner | Total investments: 7 | Find email | |
|
Andrew K. Klatt
Partner and CFO
|
Partner and CFO | Total investments: 0 | Find email | |
|
Donald C. Harrison
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
Gino Di Sciullo
Partner
|
Partner | Total investments: 0 | Find email | |
|
Jean L. Kanerva
Investment Professional
|
Investment Professional | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xlumena
|
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia frominside the GI lumen.Xlumena was founded in 2007 and is based in Mountain View, California. | $25M / Series C / Dec 03, 2013 | |
Amaranth Medical
|
Amaranth Medical‘s mission is to transform the field of interventional cardiology and beyond by providing fully bioresorbable, versatile scaffolds with unprecedented mechanical properties. We strive to become the new global standard of care for stent interventions. Amaranth is dedicated to advancing the practice of medicine and improving thelong-term health of patients worldwide.The Amaranth flower, derived from the Greek word “never fading,” stands as the emblem of our company. Like the Amaranth, a symbol of immortality and adaptability, our scaffold solutions are enduring — designed to deliver lasting clinical benefits, long after the polymeric device resorbs and disappears. | $20M / Series B / Oct 08, 2013 | |
Minimally invasive devices
|
MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselvesto degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio. | $2.5M / Series B / Jun 17, 2013 | |
|
Minimally invasive devices
|
MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselvesto degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio. | $9M / Series B / Mar 25, 2013 | |
|
Xlumena
|
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia frominside the GI lumen.Xlumena was founded in 2007 and is based in Mountain View, California. | $7M / Series B / Apr 29, 2011 | |
Prevacept Infection Control
|
Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters. | $3.1M / Series B / Aug 23, 2010 | |
|
Corepair
|
Radiofrequency devices for CHF | $4.5M / Series C / Apr 30, 2010 | |
Visioneering
|
Visioneering Technologies, Inc., headquartered in Alpharetta, Georgia, is an innovative new company that is dedicated to redefining vision. With a portfolio of technologies to address eye care issues such as presbyopia in adults and myopia correction in children, the company uses creative and differentiated design approaches to develop productsthat will ultimately enhance practitioner and patient experiences. VTI was founded by Dr. Richard A. Griffin, an optometrist, optical engineer and aerospace engineer who has spent 20 years developing VTI’s optical solutions. From Dr. Griffin's design, VTI holds fourteen issued patents worldwide that address the need for a treatment for presbyopia in the underdeveloped on-eye/in-eye categories. VTI brings together clinical, marketing, engineering, manufacturing and regulatory leaders from today's top vision care businesses. Together, these industry veterans bring the best thinking in eye care to design and bring to market new solutions for presbyopia, myopia and astigmatism. | $5M / May 11, 2009 | |
Revascular Therapeutics
|
Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels. | $3M / Series B / May 11, 2009 | |
APT Pharmaceuticals
|
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases. | $32M / Series B / Sep 30, 2008 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Charter Life Sciences invest in?
Charter Life Sciences invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Charter Life Sciences?
Public channels for Charter Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Charter Life Sciences?
The team at Charter Life Sciences includes Barr Dolan (Managing Partner), Andrew K. Klatt (Partner and CFO) and Donald C. Harrison (Managing Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
